Medical Condition News

RSS

Four-protein complex provides new target for thwarting cancer migration, invasion

The molecular machinery that switches on a gene known to cause breast cancer to spread and invade other organs has been identified by an international team led by scientists at The University of Texas M. D. Anderson Cancer Center. The paper was published Sunday in Nature Cell Biology's advanced online publication.

16 Apr 2010

Dark chocolate reduces damage to blood vessels of cirrhotic patients: Spanish research

Doctors could soon be prescribing a dose of dark chocolate to help patients suffering from liver cirrhosis and from dangerously high blood pressure in their abdomen, according to new research presented today at the International Liver CongressTM 2010, the Annual Meeting of the European Association for the Study of Liver in Vienna, Austria.

16 Apr 2010

Regulus Therapeutics' metabolic disease program data presented at Diabetes Keystone Symposium

Regulus Therapeutics Inc. today announced that new data from its metabolic disease program were presented at the "Diabetes" Keystone Symposium held April 12-17 in Whistler, British Columbia. The new pre-clinical research findings showed that therapeutic oligonucleotides targeting microRNA are able to improve insulin resistance and normalize plasma glucose in mouse models of diabetes while having no significant effect on glucose or insulin levels in normal mice.

16 Apr 2010

Study on primary cilia formation may lead to new therapies for ciliopathies

A team of scientists at the University of California, San Diego School of Medicine have identified a network of genes that initiate and manage cilia formation. Although scientists have known about cilia for decades, only recently have they discovered their role in disease. This new discovery, which may lead to new therapies for ciliopathies, will appear in the April 15 edition of Nature.

16 Apr 2010

Current screening methods for FOBT are often not appropriate

More than 75 percent of primary care physicians in the United States who order or perform the fecal occult blood test as a screening option for colorectal cancer perform an in-office test rather than relying on the home-based test, even though the home-based test is more accurate, a study by the Centers for Disease Control and Prevention has found.

16 Apr 2010

Enrollment completed in Impax Pharmaceuticals' APEX-PD trial of IPX066

Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc., today announced that it has completed enrollment of its APEX-PD trial. APEX-PD is a multinational Phase III trial of its late-stage drug candidate IPX066 in subjects with early Parkinson's disease.

16 Apr 2010

New research on EKG signals could help heart patients in future

A physics major's passion for medicine led her into research that could help heart patients in the future.

16 Apr 2010

Obesity prejudice in medical community

Prejudice towards obese people is rife among trainee health professionals, but can be modified, new research has found.

16 Apr 2010

Research may help develop simplified test for early detection of breast cancer

Researchers at the University of Arkansas are building a library of synthetically produced antibodies that can detect and rapidly validate proteins secreted by breast cancer cells. Their work will accelerate the process of developing a simple blood test for early detection of breast cancer.

16 Apr 2010

Problems faced by epileptic patients

Physicians treating patients with epilepsy are in a difficult legal situation when they have to assess their patients' ability to drive. In the current edition of the Deutsches -rzteblatt International (Dtsch Arztebl Int 2010; 107[13]: 217-23), the occupational physician Monika Gube and her coauthors describe the problems, using an individual case as an example.

16 Apr 2010

Arthritis causes more pain and limitations for African-Americans and Hispanics

Arthritis causes more pain and limitations for African-Americans and Hispanics than for whites, according to a study released today by the Centers for Disease Control and Prevention.

16 Apr 2010

Research may provide better clinical outcomes for patients with aggressive type of brain cancer

A study conducted by a collaborative team led by researchers from the University of Southern California (USC) may lead to better insight into the clinical outcome for some patients with a particularly aggressive type of brain cancer. The research may also provide a framework for development of targeted drug treatments.

16 Apr 2010

Spring is busting out all over - and so are eye allergies

Ah, spring. The time of year when trees and flowers bloom sending pollen into the air and causing sneezing, runny noses and watery eyes. The Asthma & Allergy Foundation of America estimates that 1 in 5 individuals are affected by eye allergies.

15 Apr 2010

Sonic Innovations to unveil new 12-channel BTE hearing aid at AudiologyNOW! conference

Sonic Innovations, Inc. will unveil its new 12-channel super power behind-the-ear (BTE) hearing aid, Endura, at the AudiologyNOW! conference in San Diego, California, April 14 through 17. Endura provides exceptional amplification for those suffering from severe-to-profound hearing loss.

15 Apr 2010

Celgene, Agios Pharmaceuticals form global strategic collaboration on targeting cancer metabolism

Celgene Corporation and Agios Pharmaceuticals Inc., a privately-held biotechnology company, today announced the formation of a global strategic collaboration focused on targeting cancer metabolism. The goal of the collaboration is to discover, develop, and deliver novel disease-altering therapies in oncology based on the transformational science of Agios' innovative cancer metabolism research platform. This platform is based on the concept that targeting key metabolic enzymes unique to rapidly proliferating cancer cells can "starve" the cancer.

15 Apr 2010

Positive results from NovaBay Pharmaceuticals' Phase 2a trial of NVC-422

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class anti-infectives for the treatment and prevention of antibiotic-resistant infections, today reported positive results of an open-label Phase 2a trial of NVC-422 in chronically catheterized patients with significant bacteriuria, or bacteria in the urine. The study showed that NVC-422 was well tolerated and reduced or eliminated certain pathogens in the urine.

15 Apr 2010

Momenta Pharmaceuticals to present data on M402 drug candidate at 101st AACR meeting

Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex mixture drugs, today announced that preclinical data for its novel drug candidate, M402, will be presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR). The meeting will be held April 17-21, 2010 in Washington, DC.

15 Apr 2010

Early, accurate detection of superficial bladder cancer with Olympus PDD

With Olympus photodynamic diagnosis (PDD), superficial bladder cancer can be detected earlier, easier and more accurately. Bladder cancer is diagnosed by cystoscopy, the endoscopic introduction of a light source through the urethra (transurethral) into the bladder. The imaging technology PDD uses blue light to increase the contrast between tumour tissue (red) and healthy tissue (blue).

From Evident Corporation - Life Sciences 15 Apr 2010

Æterna Zentaris Zentaris requests EMA Scientific Advice for Phase 3 program with perifosine

Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that it has requested Scientific Advice from the European Medicines Agency (EMA) to assure the acceptability of the recently initiated Phase 3 programs for the development of its lead anticancer compound, perifosine, in its two lead indications, multiple myeloma and refractory advanced colorectal cancer.

15 Apr 2010

AVANIR Pharmaceuticals presents Phase III trial data of Zenvia for PBA at AAN Annual Meeting

AVANIR Pharmaceuticals, Inc. today announced the presentation of detailed data, including safety and tolerability data from the open-label extension as well as cardiac safety data from the double-blind phase of the Phase III confirmatory STAR trial evaluating the investigational drug Zenvia™ (dextromethorphan/quinidine) in the treatment of pseudobulbar affect (PBA). The data were presented in two posters at the American Academy of Neurology (AAN) Annual Meeting in Toronto, Canada.

15 Apr 2010

Medical Condition News

Four-protein complex provides new target for thwarting cancer migration, invasion

Dark chocolate reduces damage to blood vessels of cirrhotic patients: Spanish research

Regulus Therapeutics' metabolic disease program data presented at Diabetes Keystone Symposium

Study on primary cilia formation may lead to new therapies for ciliopathies

Current screening methods for FOBT are often not appropriate

Enrollment completed in Impax Pharmaceuticals' APEX-PD trial of IPX066

New research on EKG signals could help heart patients in future

Obesity prejudice in medical community

Research may help develop simplified test for early detection of breast cancer

Problems faced by epileptic patients

Arthritis causes more pain and limitations for African-Americans and Hispanics

Research may provide better clinical outcomes for patients with aggressive type of brain cancer

Spring is busting out all over - and so are eye allergies

Sonic Innovations to unveil new 12-channel BTE hearing aid at AudiologyNOW! conference

Celgene, Agios Pharmaceuticals form global strategic collaboration on targeting cancer metabolism

Positive results from NovaBay Pharmaceuticals' Phase 2a trial of NVC-422

Momenta Pharmaceuticals to present data on M402 drug candidate at 101st AACR meeting

Early, accurate detection of superficial bladder cancer with Olympus PDD

Æterna Zentaris Zentaris requests EMA Scientific Advice for Phase 3 program with perifosine

AVANIR Pharmaceuticals presents Phase III trial data of Zenvia for PBA at AAN Annual Meeting

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News